Johnson & Johnson Invests $8.08 Billion in PROCEPT BioRobotics Corporation $PRCT

Johnson & Johnson acquired a new stake in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 357,939 shares of the company’s stock, valued at approximately $8,082,263,000. PROCEPT BioRobotics comprises about 1.0% of Johnson & Johnson’s portfolio, making the stock its 11th largest position. Johnson & Johnson owned 0.63% of PROCEPT BioRobotics as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Handelsbanken Fonder AB grew its holdings in PROCEPT BioRobotics by 46.6% during the second quarter. Handelsbanken Fonder AB now owns 26,100 shares of the company’s stock valued at $589,000 after purchasing an additional 8,300 shares during the last quarter. Mirador Capital Partners LP acquired a new position in PROCEPT BioRobotics during the 2nd quarter worth $441,000. Versant Capital Management Inc boosted its holdings in PROCEPT BioRobotics by 994.5% during the second quarter. Versant Capital Management Inc now owns 1,193 shares of the company’s stock valued at $27,000 after acquiring an additional 1,084 shares during the period. Militia Capital Management LLC acquired a new stake in shares of PROCEPT BioRobotics in the first quarter valued at about $863,000. Finally, Parallel Advisors LLC increased its stake in shares of PROCEPT BioRobotics by 445.3% in the first quarter. Parallel Advisors LLC now owns 2,950 shares of the company’s stock worth $74,000 after purchasing an additional 2,409 shares during the period. 89.46% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on PRCT. Wells Fargo & Company lowered PROCEPT BioRobotics from an “overweight” rating to an “equal weight” rating and set a $19.00 target price on the stock. in a report on Wednesday, August 5th. UBS Group cut PROCEPT BioRobotics from a “buy” rating to a “neutral” rating and set a $20.00 price objective for the company. in a research report on Tuesday, July 28th. Wall Street Zen upgraded shares of PROCEPT BioRobotics from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. Robert W. Baird set a $20.00 target price on shares of PROCEPT BioRobotics in a research report on Wednesday, August 5th. Finally, Piper Sandler reduced their price target on shares of PROCEPT BioRobotics from $35.00 to $25.00 and set an “overweight” rating for the company in a report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $28.00.

PROCEPT BioRobotics Stock Down 1.4%

Shares of PRCT stock opened at $21.65 on Friday. PROCEPT BioRobotics Corporation has a one year low of $16.67 and a one year high of $42.71. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.55 and a quick ratio of 5.35. The stock has a fifty day moving average price of $21.06 and a 200 day moving average price of $24.49. The stock has a market cap of $1.24 billion, a P/E ratio of -11.16 and a beta of 0.89.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.01). PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.62%. The business had revenue of $94.50 million during the quarter, compared to the consensus estimate of $92.77 million. During the same period last year, the firm earned ($0.35) EPS. The company’s quarterly revenue was up 19.3% compared to the same quarter last year. Analysts predict that PROCEPT BioRobotics Corporation will post -1.67 earnings per share for the current year.

Insider Buying and Selling at PROCEPT BioRobotics

In other PROCEPT BioRobotics news, CEO Larry L. Wood bought 23,900 shares of the firm’s stock in a transaction dated Friday, August 7th. The shares were acquired at an average cost of $20.85 per share, for a total transaction of $498,315.00. Following the transaction, the chief executive officer owned 23,900 shares in the company, valued at approximately $498,315. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. In the last quarter, insiders have sold 1,000 shares of company stock worth $28,480. 4.00% of the stock is currently owned by insiders.

Key Headlines Impacting PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Neutral Sentiment: Multiple law firms are soliciting investors who purchased PROCEPT shares between February 28, 2024, and February 25, 2026, to seek lead-plaintiff status. The deadline is September 22, 2026. These notices are procedural and do not represent a finding that PROCEPT violated securities laws. Hagens Berman class-action notice
• Negative Sentiment: The lawsuit alleges that PROCEPT made misleading statements or omissions regarding demand for its Aquablation-related handpieces and the gap between handpiece sales and procedures. The complaints cite repeated sales underperformance, excess customer inventory and late-quarter bulk discounts that allegedly obscured underlying demand. The allegations also challenge explanations that revenue volatility was primarily caused by temporary saline shortages. Kahn Swick & Foti class-action notice
• Negative Sentiment: Law-firm releases reference an approximately 18% share-price decline tied to the alleged inventory issues and disclosures. Continued litigation could create legal expenses, potential settlement costs and reputational damage, while the underlying inventory buildup could weigh on future unit and handpiece sales. Investors should note that the complaints contain allegations rather than proven facts. SueWallSt investor notice

PROCEPT BioRobotics Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.